Gaithersburg, MD, April 20, 2016 – MaxCyte® Inc., the leader in driving the next generation of cellbased medicines with scalable, high-performance cell transfection systems, announced today a podium presentation summarizing results of its collaboration with investigators at NIAID, NIH demonstrating therapeutic levels of gene correction being obtained in Hematopoietic Stem Cells obtained from X-linked CGD patients, at the 19th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in the following session:
Therapeutic Level CRISPR-Oligomer-Mediated Correction of X-CGD Patient Hematopoietic Stem Cells Using Non-Viral, cGMP Compliant, Scalable, and Closed System
Session Info: Targeted Genome Editing: Gene Editing in Hematopoietic Cells
Presentation Time: Wednesday May 4, 2016 3:30 PM – 5:30 PM
Room: Thurgood Marshall North/East
“This presentation will describe in vitro results and long-term engraftment and efficacy in animals, obtained by co-transfecting of CRISPR/Cas9, gRNA and oligonucleotide templates into Hematopoietic Stem Cells obtained from X-linked CGD patients using cGMP compliant clinical scale MaxCyte GT® Flow Transfection System,” said Dr. Madhusudan Peshwa, CSO and Executive Vice President of Cellular Therapies at MaxCyte. “This work exemplifies the ability to engineer cells reproducibly, at therapeutic level, using the cGMP and regulatory compliant MaxCyte GT® System for rapid clinical translation of genome-editing technologies and engineered cell-based therapeutics to develop potentially effective therapies for treatment of CGD and other genetic diseases.”
MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology. The Company’s patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of cell-based medicines.
MaxCyte’s high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, commercial and clinical grade cell engineering in a non-viral system and with low toxicity concerns. The Company’s cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte’s customers with an established regulatory path.
MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated nonviral approach to CAR therapies in a number of cancer indications, including solid tumors.
For more information visit /